… three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the … However, whether gefitinib,
erlotinib, or afatinib is most … to compare the effectiveness of gefitinib, erlotinib, and afatinib. …

… previous reports were female non-smokers, our results provide additional insights into the
efficacy of erlotinib following gefitinib failure. Based on our results, we believe there may be an …

… The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and
… and efficacy of erlotinib and gefitinib in patients with NSCLC. We concluded that gefitinib at …

… No statistical differences in PFS were observed between gefitinib and erlotinib (2.0 months
vs. … Erlotinib and gefitinib had a similar efficacy in advanced squamous cell lung cancer. The …

… We aimed to determine whether erlotinib is superior to gefitinib in efficacy. The primary end
… Finally, the efficacy data for erlotinib and gefitinib indicated that a much larger sample size …

… To the best of our knowledge, this is the first study worldwide to compare the efficacy of
erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …

… With regard to treatment efficacy for patients with EGFR-wt, … that gefitinib and erlotinib might
have almost equal efficacy for … erlotinib appears to have higher toxicity than gefitinib at each …

… efficacy difference between gefitinib and erlotinib as salvage therapy for advanced NSCLC.
The median TTF of around 3.4–5.5 months was compatible with results of clinical … the results …

… or wild-type EGFR, the effectiveness of gefitinib and erlotinib, including drug response or …
obvious disparity in drug selection between erlotinib and gefitinib in clinical practice. Type of TK …

… Our results show that afatinib was significantly associated with longer PFS compared with
gefitinib and erlotinib, even after adjustment for other potentially confounding prognostic factors…